Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Stephen R Yant"'
Autor:
Ke Peng, Walter Muranyi, Bärbel Glass, Vibor Laketa, Stephen R Yant, Luong Tsai, Tomas Cihlar, Barbara Müller, Hans-Georg Kräusslich
Publikováno v:
eLife, Vol 3 (2014)
The steps from HIV-1 cytoplasmic entry until integration of the reverse transcribed genome are currently enigmatic. They occur in ill-defined reverse-transcription- and pre-integration-complexes (RTC, PIC) with various host and viral proteins implica
Externí odkaz:
https://doaj.org/article/638f67a091d544ddb5e6fdc775e9b331
Autor:
Mini Balakrishnan, Stephen R Yant, Luong Tsai, Christopher O'Sullivan, Rujuta A Bam, Angela Tsai, Anita Niedziela-Majka, Kirsten M Stray, Roman Sakowicz, Tomas Cihlar
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e74163 (2013)
HIV-1 integrase (IN) is the target for two classes of antiretrovirals: i) the integrase strand-transfer inhibitors (INSTIs) and ii) the non-catalytic site integrase inhibitors (NCINIs). NCINIs bind at the IN dimer interface and are thought to interfe
Externí odkaz:
https://doaj.org/article/ab7f85858d794836a0e3f22e87f9d8d3
Autor:
Adrienne E. Swanstrom, Robert J. Gorelick, Jorden L. Welker, Fabian Schmidt, Bing Lu, Kelly Wang, William Rowe, Matthew W. Breed, Kristin E. Killoran, Joshua A. Kramer, Duncan Donohue, James D. Roser, Paul D. Bieniasz, Theodora Hatziioannou, Cathi Pyle, James A. Thomas, Charles M. Trubey, Jim Zheng, Wade Blair, Stephen R. Yant, Jeffrey D. Lifson, Gregory Q. Del Prete
Publikováno v:
EBioMedicine, Vol 95, Iss , Pp 104764- (2023)
Summary: Background: Long-acting subcutaneous lenacapavir (LEN), a first-in-class HIV capsid inhibitor approved by the US FDA for the treatment of multidrug-resistant HIV-1 with twice yearly dosing, is under investigation for HIV-1 pre-exposure proph
Externí odkaz:
https://doaj.org/article/b06319c89f9342968fa2a346c4e69436
Autor:
Elena Bekerman, Stephen R. Yant, Laurie VanderVeen, Derek Hansen, Bing Lu, William Rowe, Kelly Wang, Christian Callebaut
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 16 (2023)
Long-acting antiretroviral agents for preexposure prophylaxis (PrEP) represent a promising new alternative to daily oral regimens for HIV prevention. Lenacapavir (LEN) is a first-in-class long-acting capsid inhibitor approved for the treatment of HIV
Externí odkaz:
https://doaj.org/article/bd05c3d0d12a411f9917bef6f8371399
Autor:
Samuel J. Vidal, Elena Bekerman, Derek Hansen, Bing Lu, Kelly Wang, Judy Mwangi, William Rowe, Federico Campigotto, Jim Zheng, Darryl Kato, Abishek Chandrashekar, Julia Barrett, Shivani Patel, Huahua Wan, Tochi Anioke, Noe B. Mercado, Joseph P. Nkolola, Melissa J. Ferguson, William J. Rinaldi, Christian Callebaut, Wade Blair, Tomas Cihlar, Romas Geleziunas, Stephen R. Yant, Dan H. Barouch
Publikováno v:
Nature
Because no currently available vaccine can prevent HIV infection, pre-exposure prophylaxis (PrEP) with antiretrovirals (ARVs) is an important tool for combating the HIV pandemic1,2. Long-acting ARVs promise to build on the success of current PrEP str
Autor:
Tomas Cihlar, Kirsten White, Andrew Mulato, Rima Acosta, Ross Martin, Silvia Chang, Stephen R. Yant
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 86:369-377
Background Barriers to lifelong HIV-1 suppression by antiretrovirals include poor adherence and drug resistance; regimens with higher tolerance to missed doses (forgiveness) would be beneficial to patients. To model short term non-adherence, in vitro
Autor:
Rima K. Acosta, Michelle L. D’Antoni, Andrew Mulato, Stephen R. Yant, Tomas Cihlar, Kirsten L. White
Publikováno v:
Antimicrobial agents and chemotherapy. 66(5)
The integrase strand transfer inhibitor (INSTI)-based regimens bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), dolutegravir (DTG)+FTC/TAF, DTG/lamivudine (3TC), and DTG/rilpivirine (RPV) are all approved for treatment of HIV-infected p
Autor:
Qi Liu, Chien-Hung Chou, Eda Canales, Roman Sakowicz, Steven Bondy, Tomas Cihlar, Albert Liclican, Diana M. Brainard, Anita Niedziela-Majka, William Rowe, Nikolai Novikov, Shekeba Ahmadyar, John R. Somoza, Randall L. Halcomb, Cheryl K. McDonald, Carina E. Cannizzaro, Nicolas Margot, Debi Jin, George Stepan, Qiaoyin Wu, Eric Hu, Judy Mwangi, Stephanie A. Leavitt, Todd C. Appleby, Robert L. Anderson, Scott E. Lazerwith, Schroeder Scott D, Tse Winston C, Gediminas Brizgys, Rebecca Begley, Yili Xu, Scott Sellers, Scott A. Wolckenhauer, Wesley I. Sundquist, Derek Hansen, Philip Morganelli, Andrew Mulato, Sheila Clancy, Xiaohong Liu, Anna Chiu, Eric S. Daar, Renee R. Ram, S. Swaminathan, Anne E. Chester, Melanie H. Wong, Ya-Pei Liu, John O. Link, Michael Graupe, Luong K. Tsai, Christian Callebaut, Latesh Lad, William E. Lee, Rujuta A. Bam, Terrence Z. Cai, Bing Lu, John K. Ling, Roland D. Saito, Magdeleine Hung, Armando G. Villaseñor, Peter Ruane, Nikos Pagratis, Martin S. Rhee, David Koditek, Gordon Crofoot, Giuseppe A. Papalia, Stephen R. Yant, Rob Hyland, Helen Yu, Jim Zheng, Jennifer R. Zhang, Gary I. Sinclair, Jiayao Li, Eric Singer
Publikováno v:
Nature
Oral antiretroviral agents provide life-saving treatments for millions of people living with HIV, and can prevent new infections via pre-exposure prophylaxis1–5. However, some people living with HIV who are heavily treatment-experienced have limite
Autor:
Melanie H. Wong, Helen Yu, Daniel Gonik, Derek Hansen, Wesley I. Sundquist, Debi Jin, Anita Niedziela-Majka, Nikolai Novikov, William M. McDougall, Shekeba Ahmadyar, Albert Liclican, Jill M. Perreira, Andrew Mulato, George Stepan, Jennifer R. Zhang, Bing Lu, Magdeleine Hung, Giuseppe A. Papalia, Renee R. Ram, John O. Link, Kevin Chou, Abraham L. Brass, Eric E. Paoli, Stephen R. Yant, Jim Zheng, Eric Singer, Eric Hu, Tomas Cihlar, Schroeder Scott D, Tse Winston C
Publikováno v:
Nat Med
People living with HIV (PLWH) have expressed concern about the life-long burden and stigma associated with taking pills daily and can experience medication fatigue that might lead to suboptimal treatment adherence and the emergence of drug-resistant
Autor:
Rima K Acosta, Andrew Mulato, Michelle L D’Antoni, Stephen R Yant, Tomas Cihlar, Kirsten L White
Publikováno v:
Open Forum Infectious Diseases
Background The integrase strand transfer inhibitor (INSTI)-based regimens bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), dolutegravir (DTG)+FTC/TAF, DTG/lamivudine (3TC), and DTG/rilpivirine (RPV) are all used for treatment of HIV-inf